Press Releases

Date Title View
Toggle SummaryJuly 29, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryJuly 21, 2020 GenMark Diagnostics to Report Second Quarter 2020 Financial Results on August 4, 2020
CARLSBAD, Calif. , July 21, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Tuesday, August 4, 2020. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryJuly 7, 2020 GenMark Diagnostics Provides Preliminary Financial and Operational Results for Second Quarter 2020
Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth CARLSBAD, Calif. , July 07, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
View HTML
Toggle SummaryJune 29, 2020 GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)
Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow CARLSBAD, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems,
View HTML
Toggle SummaryJune 16, 2020 GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health
Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections CARLSBAD, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular
View HTML
Toggle SummaryMay 27, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 11, 2020 GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 6, 2020 GenMark Prices Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 6, 2020 GenMark Commences Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 4, 2020 GenMark Diagnostics Reports First Quarter 2020 Results
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. ("GenMark" or the "Company") (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2020 .
View HTML